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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Administering vaccines specifically to pregnant women as part
of a disease prevention strategy has not been routinely practiced,
with the major exception of protecting against neonatal tetanus.
Pregnancy continues to be a contraindication for receipt of most
live viral (e.g., measles, mumps, rubella, varicella) vaccines. In the
wake of the thalidomide tragedy [1], real or perceived risks of ter-
atogenicity have served as a deterrent to administration of many
medicines during pregnancy. Little is known about the effects of
new medications or vaccines on pregnant women since they are
often excluded from clinical research designed to determine safety.
In recent years, however, a groundswell of public and provider
opinion has developed urging reconsideration of the practice of
excluding pregnant women from drug safety studies for some vac-
cines. The morbidity and mortality following some infections (e.g.,
influenza and pertussis) can be disproportionally greater among
infants and pregnant women [2,3]. Consequently, the Advisory
Committee on Immunization Practices (ACIP) has recommended
routine immunization of pregnant women with influenza vaccine
since 1997 [2] and a dose of Tdap during every pregnancy since
2012 [4]. Future vaccines for use in pregnancy may include group
B streptococcal, Zika, and respiratory syncytial virus vaccines. The
challenges and opportunities for maternal immunization have
begun to be addressed in various vaccine stakeholder meetings.
For example, the US National Vaccine Advisory Committee (NVAC
formed a Maternal Immunization Working Group in 2012 and
issued a report in 2014 on ‘‘Reducing Patient and Provider Barriers
to Maternal Immunizations” [6].
Post-marketing surveillance of adverse events in pregnant
women is warranted, not only because of the lack of pre-licensure
vaccine safety data in pregnancy, but also to assess for rarer
adverse events in pregnant women or their infants. Unlike efficacy
or effectiveness, however, safety cannot be assessed directly. The
relative safety of a vaccine can only be inferred indirectly from
the absence of multiple possible adverse events following immu-
nizations (AEFI) that have been assessed in a relatively large pop-
ulation. Historically, there was relatively little standardization of
case definitions for AEFI [7]. This resulted in a huge missed oppor-
tunity for meaningful comparison of safety data across vaccine tri-
als and studies in pre- and post-licensure settings, which in turn
hindered our ability to advance the science of vaccine safety.
The Brighton Collaboration was formed in 2000 to help over-
come these shortcomings [7]. Over 30 standardized case defini-
tions (with accompanying guidelines on data collection) have
since been developed by global experts for use in various settings,
arrayed by the level of available evidence. The Brighton Collabora-
tion case definitions are recommended for use by normative bodiessuch as the FDA, the European Medicines Agency, the US Centers
for Disease Control and Prevention (CDC), and the European Centre
for Disease Prevention and Control [8].
Recent studies of Guillain-Barré syndrome (GBS) [9–11] and
narcolepsy [12–14] after influenza vaccination in multiple coun-
tries used Brighton case definitions for these conditions, thereby
increasing their scientific comparability. Brighton case definitions
can also be important during public health emergencies as exem-
plified by the recent development of a microcephaly definition
(and use of the GBS case definition) [15] in response to the Zika
outbreak in the Americas [16].
Pregnant women and their infants constitute a special popula-
tion group where safety monitoring for adverse events is becoming
an important activity as new vaccines are being developed and
become recommended for use in the near future [5]. The develop-
ment of standard definitions for pregnant women and infant out-
comes would be a great benefit to research efforts aimed at
monitoring vaccine safety in these populations. Accordingly, the
World Health Organization (WHO) and Brighton Collaboration
jointly convened a meeting in July 2014 to develop Brighton
Collaboration definitions of key terms used for monitoring the
safety of immunization in pregnant women and infants [17]. As
described by Bonhoeffer et al. [18] in this special issue, this
2-day meeting led to the formation of the Global Alignment of
Immunization safety Assessment in pregnancy (GAIA) project
funded by the Bill and Melinda Gates Foundation. This special issue
of Vaccine includes the hard work by members of the GAIA project
working groups with the development of five obstetric case defini-
tions (Non-reassuring fetal status, Maternal death, Postpartum
hemorrhage, Hypertensive disorders of pregnancy, and Preterm
birth) and five neonatal case definitions (Congenital anomalies,
Neonatal death, Neonatal infections, Preterm birth, Stillbirth) in
the first year. Meanwhile, the next ten GAIA case definitions are
under development, including: (1) Obstetric: Abortion, Antenatal
bleeding, Gestational diabetes, Dysfunctional labor, Fetal growth
retardation; and, (2) Neonatal: Low birth weight, Small for gesta-
tional age, Neonatal encephalopathy, Respiratory distress, Failure
to thrive. These additional GAIA case definitions will be published
together in a future special issue of Vaccine when ready.
The more than 200 volunteers from 13 organizations who
formed the ten case definition working groups are to be
congratulated for their willingness to cross their traditional ‘‘silos”
(e.g., vaccines, obstetrics, neonatology) in this large collaboration.
In addition to the main case definitions themselves, the GAIA col-
laboration has developed several associated tools to facilitate their
use. These tools include: (1) guidelines for harmonized data
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(2) a data collection matrix; (3) a glossary and ontology of terms
enabling mapping of the case definitions to several main disease
codes used in electronic health care databases; and (4) an online
tool for automated case classification of text descriptions of AEFI.
These tools will also be published in one of the special Vaccine
issues on GAIA when ready and available on the GAIA and Brighton
Collaboration websites. With such a solid scientific foundation, we
can be optimistic that the field of maternal immunizations, espe-
cially our understanding of its safety, can now advance. In an era
of increased vaccine hesitancy and skepticism [19], GAIA may
serve as a model for how one realm of immunizations can move
from the fear of the unknown to a sound evidence base.
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